Michele Mondini, PhD, is a team leader in the INSERM U1030 unit, Molecular Radiotherapy and Therapeutic Innovation, at Gustave Roussy in Villejuif, France.

He earned his PhD in Immunology and Cellular Biology from the University of Turin, Italy. He later served as CEO and scientific supervisor of Notopharm, an Italian start-up focused on the diagnosis and treatment of immune-related disorders.

Dr. Mondini joined INSERM U1030 at Gustave Roussy in 2011, where his research has since centered on the immune system’s role in responses to radiotherapy. Now a tenured INSERM research scientist and team leader, his work investigates the effects of ionizing radiation on both tumor and healthy tissues. He is particularly focused on the preclinical development of radiotherapy combined with immuno-oncology approaches and has a special interest in innovative irradiation techniques such as spatial fractionation.

He serves as an Associate Editor for the Journal of Translational Medicine and is a member of the steering committees of both the French Society for Radiation Biology (SFBR) and the Italian Association for Radiobiology (AIRB). Dr. Mondini has authored over 70 scientific publications in the fields of radiotherapy, immunotherapy, inflammation, and autoimmunity, and is listed as an inventor on five patent applications.